Search the Newsreel

H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18

H.C. Wainwright has reiterated its Buy rating on Aura Biosciences (AURA.US) and maintained its price target of $18. This indicates the firm's continued confidence in the company's prospects. Investors will be watching for further developments from Aura Biosciences.

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac …

Adage Capital discloses 9.1M Aura Biosciences (AURA) shares under shared control

Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?

Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding

Adage Capital Management, L.P. and its affiliated entities have reported a beneficial ownership of 3.41% in Bright Minds Biosciences Inc. (DRUG) through a Schedule 13G/A filing. This stake, totaling 335,000 common shares, reflects shared voting and dispositive power among the reporting persons, including Robert …

Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript

Agios Pharmaceuticals reported strong Q4 and full-year 2025 results, driven by the successful launch of AQVESME for thalassemia and robust PYRUKYND revenue. The company ended 2025 with $1.2 billion in cash, has a clear path to profitability, and is advancing its pipeline, including a …

Cellectar Biosciences Q2 2026 Earnings Preview

* Cellectar Biosciences (CLRB [https://seekingalpha.com/symbol/CLRB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. * The consensus EPS Estimate is -$0.52 [https://seekingalpha.com/symbol/CLRB/earnings/estimates] (+84.7% Y/Y) and the consensus Revenue Estimate is $0M * Over the last 1 year, CLRB has …

Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug

Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to …

Why Microbix Biosystems Inc. stock is rising today

Helios Technologies (NYSE:HLIO) Price Target Raised to $110.00 at JPMorgan Chase & Co.

JPMorgan Chase & Co. has raised its price target for Helios Technologies (NYSE:HLIO) to $110.00 from $100.00, maintaining an "overweight" rating and implying a significant upside. This comes after Helios Technologies reported strong quarterly earnings, beating analyst estimates with an EPS of $0.88 and …

Pacira (PCRX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Susan Mesco Chief Executive Officer - Frank Lee Chief Commercial Officer - Brendan Teehan Chief Financial Officer - Shawn Cross Chief Administrative Officer …

Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings

SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary

Spruce Biosciences, Inc. (SPRB) reported a significantly widened net loss of $(16.2M) in 2Q 2026, compared to $(2.1M) in 2Q 2025, with diluted loss per share increasing to $(6.68). The company did not report revenue but highlighted regulatory progress with TA-ERT receiving FDA Breakthrough …

Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M

Spruce Biosciences (SPRB) reported an increased net loss of $28.5 million for the first half of 2026, up from $16.1 million in 2025, primarily due to higher research and development expenses for its lead asset, tralesinidase alfa (TA-ERT). Despite increased spending, the company significantly …

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …

Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings

Emergent BioSolutions' Executive Vice President and Chief Growth Officer, Stephanie Duatschek, has reported her initial equity holdings, which include 197,416 shares of common stock and various employee stock options. Her holdings comprise 55,639 direct common shares and 141,777 unvested Restricted Stock Units (RSUs), with …

Spruce Biosciences (SPRB) doubles cash as TA-ERT BLA and $5.5M backing advance

Spruce Biosciences GAAP EPS of -$6.68

* Spruce Biosciences press release [https://seekingalpha.com/pr/20616630-spruce-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SPRB [https://seekingalpha.com/symbol/SPRB]): Q2 GAAP EPS of -$6.68. * Cash and cash equivalents as of June 30, 2026 were $96.3 million, compared to $48.9 million as of December 31, 2025. * Spruce believes that its cash and cash equivalents …

Spruce Biosciences: Q4 Biologics Filing Anticipated; Child Study Expected

Spruce Biosciences receives $5.5M from patient advocacy groups

Spruce Biosciences (NASDAQ:SPRB) has secured a $5.5 million strategic investment from the Cure Sanfilippo Foundation and the National MPS Society. This funding will partially support an expanded access program for its investigational therapy, tralesinidase alfa enzyme replacement therapy (TA-ERT), aimed at patients with Sanfilippo …

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages

Cogent Biosciences (NASDAQ:COGT) has received an average "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $45.90. The company recently reported quarterly EPS of -$0.52, exceeding the consensus estimate. Institutional investors have also increased their holdings in the company.

HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

HC Wainwright has revised its Q3 2026 earnings estimate for Solid Biosciences (NASDAQ:SLDB), predicting a narrowed loss of $0.38 per share and maintaining a "Buy" rating with a $25 price target. The firm anticipates Solid Biosciences will become profitable by 2029, projecting earnings of …

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported Earnings, And Analysts Cut Their Target Price

Analysts Offer Predictions for AURA Q1 Earnings

Medios steigert Umsatz im ersten Halbjahr 2026 auf über 1 Milliarde Euro, senkt aber die Gewinnprognose

Helios Towers Sets Dollar Exchange Rate for 2026 Interim Dividend

Equities Analysts Set Expectations for PCRX Q3 Earnings

Aroa Biosurgery (ASX:ARX) Profit Milestone Shifts Focus to US Growth Strategy

Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results

Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Helios Technologies, Inc $HLIO Stake Cut by Wasatch Advisors LP

Wasatch Advisors LP significantly reduced its stake in Helios Technologies (HLIO) by 17.4% in the second quarter, selling 138,923 shares but still retaining a substantial holding valued at approximately $58.9 million. This comes as Helios Technologies exceeded its second-quarter earnings and revenue expectations, and …

(PCRX) and the Role of Price-Sensitive Allocations

This article analyzes Pacira Biosciences Inc

Beijing Biostar Pharmaceuticals Sets Board Meeting to Review Interim Results and Dividend

Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO